Find and sign up for a retatrutide clinical trial

Find a retatrutide study

Choose a country and check which studies are marked recruiting. The official record has eligibility criteria and site contacts; the study team decides whether you can participate.

How to sign up for a retatrutide trial

You sign up through a study site, not through a central form. Find a study that is recruiting near you in the list above, open its official record, and contact the listed site. The site screens you and decides whether you are eligible.

1. Pick a recruiting study. “Active, not recruiting” means the study is closed to new participants.
2. Check the sponsor. Lilly-sponsored studies list Eli Lilly and Company as the lead sponsor. Confirm a study on Lilly’s official study finder before you share medical information. A study with a different lead sponsor won’t appear there, so verify the site independently first.
3. Read the eligibility criteria. Studies may require a particular condition, age range or treatment history. Some are for a specific disease, not general weight loss.
4. Check the nearest site. Overall recruitment status does not mean every location is accepting participants.
5. Contact the site and ask what participation involves. Confirm visits, travel, tests, costs and whether the study includes a placebo or another medicine. Your own doctor can also help with a referral.

Can I sign up if I’m not near a study site?

Studies enroll through their listed locations. If no recruiting site is within reach, check the list again later: new sites and studies are added as the registry is updated.

Is signing up a way to get retatrutide?

Not reliably. Joining a study does not guarantee you receive retatrutide, because many studies compare it with placebo or another medicine, and access after the study is not guaranteed.

Read the trial application guide →

Looking for results?

Lilly reported TRIUMPH-2 and TRIUMPH-3 topline results on July 23, 2026. Both measured weight loss at 80 weeks in different populations. Those announcements are evidence updates, not recruitment notices.

• All trial results: populations, endpoints and evidence
• TRIUMPH-3: severe obesity and cardiovascular disease
• What weight-loss results mean for expectations

Approval and access are separate questions

In its July 23 announcement, Lilly said it plans to submit a US approval application in Q1 2027. A planned filing is not an approval or a confirmed launch date.

See the approval timeline for confirmed milestones and the cost and access guide for the distinction between trials, expanded access and commercial availability.